Joint Program in Nuclear Medicine

Solitary Bone Metastasis in Breast Cancer

Laurent Dinh, MD
Milos J. Janicek, MD, PhD

October 26, 1993

Presentation

A 57 year old female with stage II a breast cancer, complained of back pain, without any history of trauma.

Imaging Findings

Bone scintigraphy (45k bytes) with a spot view (41k bytes) of the left ribs demonstrated a suspicious dumbbell shaped lesion in the left 8th rib. Correlation with X-ray revealed two simple rib fractures on the same rib.

Discussion

Breast cancer is the most common form of malignant disease among women; one in every ten women in the United States will suffer from this disease. It represents the second leading cause of death by a malignant disease in women after lung cancer. Bone metastasis in breast cancer are common. The risk of developing bone metastasis increases with the stage of the disease at presentation. Autopsy studies have demonstrated a high proportion of breast cancer patients with bone metastasis (50-85%%).

About 6 to 21%% of metastatic bone disease from all extraosseous primaries will appear initially as a single focus. In Boxer et al's series of breast cancer patients with relapse to bone, 21%% of patients relapsed to bone with a single demonstrable metastasis. Solitary bone scintigraphic abnormality was due to metastasis in 11%% of cases in Jacobson et al' s report on breast cancer patients. This variation in probability of metastatic bone disease may be due to the different location of the solitary bone abnormality as well as the different types of malignant tumor. Lesions in the axial skeleton are the most suspicious for metastatic disease. Boxer et al reported that 88%% of patients with a single bone metastasis were in the spine. Jacobson et al looked at the scintigraphic pattern of metastatic bone disease in breast cancer patients with less than 5 new bone scan abnormalities and reported that 56%% of the bone metastasis are in the spine and only 6%% in the ribs. Interestingly enough, rib lesions were the most common new bone scintigraphic abnormality. In Jacobson et al's series, 85 out of 306 new bone scan abnormalities were rib lesions, but only 7%% of these lesions were malignant.

When solitary lesion is identified on bone scintigraphy, further evaluation is required. Appropriate plain X-rays should be obtained to seek benign etiology. It has been reported that when the correlative X-rays were interpreted as normal, 17 %% of the lesions turned out to be malignant; but when the plain X-rays revealed a benign process, only 1%% of the lesions were malignant.

Conclusion:

Bone scintigraphy is a very sensitive test to detect bone abnormality, but it lacks specificity. New solitary bone abnormality on bone scintigraphy requires further evaluation. As a rule, if the plain X-ray reveals a benign process, a malignant cause is unlikely, but if it is unrevealing, further investigation with CT, MRI or follow-up studies are needed to determine the diagnosis.

References

1-McNeil BJ: Value of bone scanning in neoplastic disease, Seminar in nuclear medicine, vol. XIV, 4: 277-286,1984.

2-Jacobson AF, Stomper PC, Cronin EB, Kaplan WD: Bone scans with one or two new abnormalities in cancer patients with no known metastases: Reliability of interpretation of initial correlative radiographs, Radiology,174:503-507, 1990.

3-Jacobson AF, Stomper PC, Jochelson Ms. Ascoli DM, Henderson, IC, Kaplan WD: Association between number and sites of new bone scan abnormalities and presence of skeletal metastases in patients with breast cancer, J Nucl Med. 31: 387-392, 1990.

4-Boxer DI, Colin EC, Coleman R, Fogelman I: Bone secondaries in breast cancer: the solitary metastasis, J Nuc Med., 30: 1318-1320, 1989.

5-Tumeh SS, Beadle G, Kaplan WD: Clinical significance of solitary rib lesions in patients with extraskeletal malignancy, J Nuc Med. 26: 1140-1143,1985.

6-Holder LE: Clinical radionuclide bone imaging, Radiology, 176: 607-614, 1990.

7-Svensson GK, Chin L, Siddon RL, Harris Jr: Breast treatment techniques at the joint Center for Radiation Therapy. In Conservative Management of Breast Caner, Harris Jr, Hellman S, Silen W, eds. Philadelphia, Lippincott and Co.,pp 239-255, 1983.

Click here to go to Joint Program in Nuclear Medicine home page and Copyright notice.


J. Anthony Parker, MD PhD, Tony_Parker@bidmc.harvard.edu